Carcinoma News and Research RSS Feed - Carcinoma News and Research

Carcinoma is cancer that begins in the skin or in tissues that line or cover internal organs.
ASTRO honors Ms. Keresztes with 2016 Survivor Circle Award

ASTRO honors Ms. Keresztes with 2016 Survivor Circle Award

The American Society for Radiation Oncology has chosen Theresa A. Keresztes, a resident of Wellesley, Massachusetts, to receive the 2016 Survivor Circle Award. [More]
Study shows many nonmelanoma skin cancer patients still get sunburned

Study shows many nonmelanoma skin cancer patients still get sunburned

A recent study by researchers at Johns Hopkins concludes that a substantial number of people with a history of the most frequent kind of nonmelanoma skin cancers still get sunburned at the same rate as those without previous history, probably because they are not using sun-protective methods the right way or in the right amounts. [More]
New method helps characterize immune cells in tumor tissues

New method helps characterize immune cells in tumor tissues

Despite recent achievements in the development of cancer immunotherapies, only a small group of patients typically respond to them. Predictive markers of disease course and response to immunotherapy are urgently needed. [More]
Expanding the potential of existing cancer therapies: an interview with Dr Mark Rutstein

Expanding the potential of existing cancer therapies: an interview with Dr Mark Rutstein

Cancer remains a leading cause of death worldwide, and the global cancer burden is expected to increase by 70 percent over the next two decades. [More]
Low levels of blood selenium may increase risk of liver cancer

Low levels of blood selenium may increase risk of liver cancer

A new study, published in current issue of The American Journal of Clinical Nutrition, shows that the highest levels of blood selenium or of selenoprotein P, the protein that distributes selenium from the liver around the body, are associated with a decreased risk of developing liver cancer (particularly hepatocellular carcinoma), even when all other major liver cancer risk factors are taken into account. [More]
CNIO study shows proinflammatory molecule IL-17A can be key factor in development of NASH and HCC

CNIO study shows proinflammatory molecule IL-17A can be key factor in development of NASH and HCC

Non-alcoholic steatohepatitis (NASH) is a serious hepatic condition that precedes hepatocellular carcinoma (HCC) and is currently untreatable. [More]
Scientists detect first cell from which tumour grows in skin cancers

Scientists detect first cell from which tumour grows in skin cancers

Scientists have identified for the first time the 'cell of origin' - in other words, the first cell from which the cancer grows - in basal cell carcinoma, the most common form of skin cancer, and followed the chain of events that lead to the growth of these invasive tumours. [More]
Researchers identify potential biomarkers predictive of TKIs response in metastatic renal cancer

Researchers identify potential biomarkers predictive of TKIs response in metastatic renal cancer

A team of CNIO researchers, in collaboration with the Spanish Oncology Genitourinary Group and the University Hospitals Leuven, has discovered various potential biomarkers predictive of tyrosine kinase inhibitors (TKIs) response in metastatic renal cancer. [More]
FIB-4 index predicts HBV-related HCC

FIB-4 index predicts HBV-related HCC

Japanese researchers reveal an association between elevated FIB-4 index 24 weeks after the initiation of nucleos(t)ide analogue therapy and the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. [More]
Infant HBV vaccination prevents HCC in children, young adults

Infant HBV vaccination prevents HCC in children, young adults

Immunisation against hepatitis B virus in infants protects against the development of hepatocellular carcinoma in not only children but also young adults, a Taiwanese study finds. [More]
TAILOR study shows treatment with Erbitux plus FOLFOX improves survival in RAS wild-type mCRC patients

TAILOR study shows treatment with Erbitux plus FOLFOX improves survival in RAS wild-type mCRC patients

Merck, a leading science and technology company, will present data at the ESMO 18th World Congress on Gastrointestinal Cancer from the pivotal Phase III TAILOR study in patients from China, the first prospective trial to evaluate an anti-EGFR antibody in the first-line therapy of patients with RAS wild-type metastatic colorectal cancer (mCRC). [More]
New technique can help identify aggressive forms of DCIS

New technique can help identify aggressive forms of DCIS

When a woman is diagnosed with the earliest stage of breast cancer, how aggressive should her treatment be? Will the non-invasive cancer become invasive? Or is it a slow-growing variety that will likely never be harmful? [More]
Regorafenib drug improves survival rates in patients with hepatocellular carcinoma

Regorafenib drug improves survival rates in patients with hepatocellular carcinoma

Oral multikinase inhibitor regorafenib achieves significantly improved survival rates compared to placebo in patients with hepatocellular carcinoma, according to data from the phase III RESORCE trial, presented at the ESMO 18th World Congress of Gastrointestinal Cancer in Barcelona, Spain. [More]
Study focuses on critical proteins involved in ovarian cancer biology

Study focuses on critical proteins involved in ovarian cancer biology

In what is believed to be the largest study of its kind, scientists at the Pacific Northwest National Laboratory, Johns Hopkins University and their collaborators from institutions across the nation have examined the collections of proteins in the tumors of 169 ovarian cancer patients to identify critical proteins present in their tumors. [More]
Immunotherapy-treated cancer patients may develop rheumatic disorders

Immunotherapy-treated cancer patients may develop rheumatic disorders

Oncologists need to be aware of the potential for rheumatological diseases in patients with cancer following treatment with immune checkpoint inhibitors, say US investigators. [More]
Compounds extracted from parsley and dill seeds may help fight cancer

Compounds extracted from parsley and dill seeds may help fight cancer

A team of Russian scientists from Moscow Institute of Physics and Technology, the N. D. Zelinsky Institute of Organic Chemistry, the Institute of Developmental Biology, and the Institute of Cell Biophysics proposed an efficient approach to a novel agents with anticancer activity. [More]
Scientists find link between makeup of individual's microbiome and head and neck cancer

Scientists find link between makeup of individual's microbiome and head and neck cancer

In a sample study, researchers at Johns Hopkins say they have found an association between the makeup of an individual's microbiome and head and neck cancer, a finding that potentially advances the quest for faster and more accurate cancer diagnosis and therapy. [More]
Taking ipilimumab, nivolumab drugs may increase risk of developing rheumatologic diseases

Taking ipilimumab, nivolumab drugs may increase risk of developing rheumatologic diseases

Case reports on 13 cancer patients suggest that a small number of cancer patients taking the immunotherapy drugs ipilimumab and nivolumab may be at some higher-than-normal risk of developing autoimmune joint and tissue diseases, including inflammatory arthritis, according to a preliminary study by Johns Hopkins Medicine researchers. [More]
HCC predictors identified for chronic HBV patients with newly diagnosed cirrhosis

HCC predictors identified for chronic HBV patients with newly diagnosed cirrhosis

In patients with chronic hepatitis B virus infection who have been newly diagnosed with cirrhosis, the risk of hepatocellular carcinoma development can be ascertained using several clinical and molecular factors, study findings indicate. [More]
Cytoreductive nephrectomy can extend survival of metastatic kidney cancer patients

Cytoreductive nephrectomy can extend survival of metastatic kidney cancer patients

Surgery to remove a cancerous kidney can often lengthen the lives of patients receiving targeted therapy for metastatic kidney cancer, but only about three in ten such patients undergo the procedure, according to a new study by researchers at Dana-Farber Cancer Institute and Brigham and Women's Hospital. [More]
Advertisement